Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 92

1.

Loss of STAT3 in Lymphoma Relaxes NK Cell-Mediated Tumor Surveillance.

Putz EM, Hoelzl MA, Baeck J, Bago-Horvath Z, Schuster C, Reichholf B, Kern D, Aberger F, Sexl V, Hoelbl-Kovacic A.

Cancers (Basel). 2014 Jan 27;6(1):193-210. doi: 10.3390/cancers6010193.

PMID:
24473086
[PubMed]
Free PMC Article
2.

Loss of STAT3 in murine NK cells enhances NK cell-dependent tumor surveillance.

Gotthardt D, Putz EM, Straka E, Kudweis P, Biaggio M, Poli V, Strobl B, Müller M, Sexl V.

Blood. 2014 Sep 2. pii: blood-2014-03-564450. [Epub ahead of print]

PMID:
25185262
[PubMed - as supplied by publisher]
3.

The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines.

Roda JM, Joshi T, Butchar JP, McAlees JW, Lehman A, Tridandapani S, Carson WE 3rd.

Clin Cancer Res. 2007 Nov 1;13(21):6419-28. Epub 2007 Oct 25.

PMID:
17962339
[PubMed - indexed for MEDLINE]
Free Article
4.

Histone deacetylase inhibitors impair NK cell viability and effector functions through inhibition of activation and receptor expression.

Rossi LE, Avila DE, Spallanzani RG, Ziblat A, Fuertes MB, Lapyckyj L, Croci DO, Rabinovich GA, Domaica CI, Zwirner NW.

J Leukoc Biol. 2012 Feb;91(2):321-31. doi: 10.1189/jlb.0711339. Epub 2011 Nov 28.

PMID:
22124136
[PubMed - indexed for MEDLINE]
Free Article
5.

Differential utilization of Janus kinase-signal transducer activator of transcription signaling pathways in the stimulation of human natural killer cells by IL-2, IL-12, and IFN-alpha.

Yu CR, Lin JX, Fink DW, Akira S, Bloom ET, Yamauchi A.

J Immunol. 1996 Jul 1;157(1):126-37.

PMID:
8683106
[PubMed - indexed for MEDLINE]
6.

Novel role for STAT3 in transcriptional regulation of NK immune cell targeting receptor MICA on cancer cells.

Bedel R, Thiery-Vuillemin A, Grandclement C, Balland J, Remy-Martin JP, Kantelip B, Pallandre JR, Pivot X, Ferrand C, Tiberghien P, Borg C.

Cancer Res. 2011 Mar 1;71(5):1615-26. doi: 10.1158/0008-5472.CAN-09-4540. Epub 2011 Jan 21.

PMID:
21257710
[PubMed - indexed for MEDLINE]
Free Article
7.

Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines.

Luedke E, Jaime-Ramirez AC, Bhave N, Roda J, Choudhary MM, Kumar B, Teknos TN, Carson WE 3rd.

Surgery. 2012 Sep;152(3):431-40. doi: 10.1016/j.surg.2012.05.035. Epub 2012 Jul 6.

PMID:
22770960
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Altered IFNgamma signaling and preserved susceptibility to activated natural killer cell-mediated lysis of BCR/ABL targets.

Cebo C, Voutsadakis IA, Da Rocha S, Bourhis JH, Jalil A, Azzarone B, Turhan AG, Chelbi-Alix M, Chouaib S, Caignard A.

Cancer Res. 2005 Apr 1;65(7):2914-20.

PMID:
15805294
[PubMed - indexed for MEDLINE]
Free Article
9.

Frequent STAT3 activation is associated with Mcl-1 expression in nasal NK-cell lymphoma.

Tsutsui M, Yasuda H, Suto H, Imai H, Isobe Y, Sasaki M, Kojima Y, Oshimi K, Sugimoto K.

Int J Lab Hematol. 2010 Aug 1;32(4):419-26. doi: 10.1111/j.1751-553X.2009.01204.x. Epub 2009 Nov 24.

PMID:
19968719
[PubMed - indexed for MEDLINE]
10.

Targeting Stat3 induces senescence in tumor cells and elicits prophylactic and therapeutic immune responses against breast cancer growth mediated by NK cells and CD4+ T cells.

Tkach M, Coria L, Rosemblit C, Rivas MA, Proietti CJ, Díaz Flaqué MC, Beguelin W, Frahm I, Charreau EH, Cassataro J, Elizalde PV, Schillaci R.

J Immunol. 2012 Aug 1;189(3):1162-72. doi: 10.4049/jimmunol.1102538. Epub 2012 Jun 29.

PMID:
22753933
[PubMed - indexed for MEDLINE]
Free Article
11.

Recruitment of natural killer cells in advanced stages of endogenously arising B-cell lymphoma: implications for therapeutic cell transfer.

Przewoznik M, Hömberg N, Naujoks M, Pötzl J, Münchmeier N, Brenner CD, Anz D, Bourquin C, Nelson PJ, Röcken M, Mocikat R.

J Immunother. 2012 Apr;35(3):217-22. doi: 10.1097/CJI.0b013e318247440a.

PMID:
22421939
[PubMed - indexed for MEDLINE]
12.

Interferon-gamma: biologic functions and HCV therapy (type I/II) (1 of 2 parts).

Gattoni A, Parlato A, Vangieri B, Bresciani M, Derna R.

Clin Ter. 2006 Jul-Aug;157(4):377-86. Review. Retraction in: Clin Ter. 2008 May-Jun;159(3):207.

PMID:
17051976
[PubMed - indexed for MEDLINE]
13.

Experimental appraisal of the lack of antitumor natural killer cell-mediated immunosurveillance in response to lymphomas growing in the mouse brain.

Yamasaki T, Moritake K, Klein G.

J Neurosurg. 2003 Mar;98(3):599-606.

PMID:
12650434
[PubMed - indexed for MEDLINE]
14.

NK cells are the crucial antitumor mediators when STAT3-mediated immunosuppression is blocked in hepatocellular carcinoma.

Sui Q, Zhang J, Sun X, Zhang C, Han Q, Tian Z.

J Immunol. 2014 Aug 15;193(4):2016-23. doi: 10.4049/jimmunol.1302389. Epub 2014 Jul 11.

PMID:
25015826
[PubMed - in process]
15.

STAT3 transcription factor is constitutively activated and is oncogenic in nasal-type NK/T-cell lymphoma.

Coppo P, Gouilleux-Gruart V, Huang Y, Bouhlal H, Bouamar H, Bouchet S, Perrot C, Vieillard V, Dartigues P, Gaulard P, Agbalika F, Douay L, Lassoued K, Gorin NC.

Leukemia. 2009 Sep;23(9):1667-78. doi: 10.1038/leu.2009.91. Epub 2009 May 7.

PMID:
19421230
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Hematological malignancies escape from NK cell innate immune surveillance: mechanisms and therapeutic implications.

Farnault L, Sanchez C, Baier C, Le Treut T, Costello RT.

Clin Dev Immunol. 2012;2012:421702. doi: 10.1155/2012/421702. Epub 2012 Aug 1. Review.

PMID:
22899948
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Leukemic challenge unmasks a requirement for PI3Kdelta in NK cell-mediated tumor surveillance.

Zebedin E, Simma O, Schuster C, Putz EM, Fajmann S, Warsch W, Eckelhart E, Stoiber D, Weisz E, Schmid JA, Pickl WF, Baumgartner C, Valent P, Piekorz RP, Freissmuth M, Sexl V.

Blood. 2008 Dec 1;112(12):4655-64. doi: 10.1182/blood-2008-02-139105. Epub 2008 Aug 6.

PMID:
18684865
[PubMed - indexed for MEDLINE]
Free Article
18.
19.
20.

The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity.

Salih J, Hilpert J, Placke T, Grünebach F, Steinle A, Salih HR, Krusch M.

Int J Cancer. 2010 Nov 1;127(9):2119-28. doi: 10.1002/ijc.25233.

PMID:
20143399
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk